PVX108 peanut allergy shots more than double tolerated peanut in Phase 2 trial in children
Aravax says monthly shots of its seven peptide immunotherapy raised the amount of peanut children tolerated 2.4 fold against 1.2 fold on placebo, with no anaphylaxis. The higher dose group held 23 children and a larger trial is still needed.
What's new
Aravax reported that monthly PVX108 shots met the primary endpoint of a Phase 2 trial in 71 children aged 4 to 11 with peanut allergy, with no anaphylaxis or treatment related serious events.
Why it matters
Most people with peanut allergy go untreated, and whole peanut protein is too risky for classic allergy shots; PVX108 uses short T cell peptides that do not bind IgE.
What's next
Full data go to a European allergy meeting on 20 November, open label extension results are due in the second half of 2027, and a larger trial is still needed.
A monthly PVX108 peanut allergy shot more than doubled the amount of peanut that children could eat without a reaction in a Phase 2 trial, Australian developer Aravax reported. The results were presented on 14 November at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Phoenix. The peptide immunotherapy caused no anaphylaxis or serious treatment related events in the 71 children of the main cohort. The investigator called the effect modest but likely meaningful, and larger trials are still needed.
How the PVX108 trial was run
The trial, registered as NCT05621317, enrolled 95 people at 14 sites in the United States and Australia. A pilot cohort of 24 adolescents aged 12 to 17 tested safety first. The main efficacy and safety cohort then randomized 71 children aged 4 to 11 to one of two dose levels of PVX108 or to placebo, given once a month as a shot into the skin for 12 months. At the end of that year, each child took a double blind, placebo controlled oral food challenge, eating rising amounts of peanut protein under supervision until a reaction appeared. The challenge followed the PRACTALL guidelines, a shared standard for allergy trials. Of the 71 children, 68 finished treatment and the primary challenge, and none withdrew because of the study drug.
PVX108 is made of seven short peptides. Each copies a fragment of a major peanut allergen that T cells recognize, according to Aravax. The fragments are too small to bind IgE, the antibody that sets off allergic reactions, so they are meant to retrain the T cells that drive the allergy without triggering a reaction to the shot itself. Brian Vickery of Emory University and Children's Healthcare of Atlanta presented the data. He said in an interview with MedPage Today that whole peanut protein cannot safely be given as a classic allergy shot. Jay Lieberman of the University of Tennessee Health Science Center agreed, saying that approach "caused too many reactions." Aravax says the FDA has granted PVX108 Fast Track designation for peanut allergy.
PVX108 peanut allergy results at 12 months
The primary endpoint compared the change in the highest amount of peanut each child tolerated at the food challenge. On the higher dose, that amount rose 2.4 fold from baseline after 12 months, against 1.2 fold on placebo, a statistically significant gap in the intention to treat analysis, Aravax said. The higher dose group held 23 children and the placebo group 24. Reactions also became milder. When children were challenged at the amount that had caused a reaction at baseline, 67% of reactions on the higher dose were absent or mild, compared with 35% on placebo. In a further cumulative threshold measure, 39.4% of children on the higher dose passed against 16.7% on placebo. The lower dose gave weaker signals across most endpoints.
On the higher dose, that amount rose 2.4 fold from baseline after 12 months, against 1.2 fold on placebo, a statistically significant gap in the intention to treat analysis, Aravax said.
Vickery said the protection reached is more than double the amount that typically causes accidental reactions when families try to avoid peanut. He told MedPage Today that earlier work suggests a gain of that size is probably clinically meaningful for most patients. He also acknowledged that it is likely smaller than what oral immunotherapy achieves, where children swallow peanut protein every day. The trade off, he argued, is safety and burden: a monthly shot against daily dosing, which in some oral trials led to anaphylaxis in a minority of participants. Aravax also reported better peanut skin prick test results and an improvement in the emotional impact score that children rated themselves on the higher dose.
Safety record and the gap it may fill
Safety results were clean in this small group. There were no treatment related allergic events, no anaphylaxis and no treatment related serious adverse events at either dose. Treatment related adverse events of any kind occurred in one child on placebo, two on the lower dose and three on the higher dose, none above grade 2, and most were reactions at the injection spot. The table below gathers the main figures Aravax released for the 71 child cohort. They come from a company announcement and a meeting talk, not yet from a peer reviewed paper, and the trial was not large enough to detect rare harms.
| Measure | Higher dose | Placebo |
|---|---|---|
| Children randomized | 23 | 24 |
| Fold change in tolerated peanut at month 12 | 2.4 | 1.2 |
| Reactions absent or mild at baseline reactive amount | 67% | 35% |
| Passed the cumulative threshold | 39.4% | 16.7% |
| Children with a treatment related adverse event | 3 (13%) | 1 (4.2%) |
The need is large. Vickery said millions of people live with peanut allergy and most receive no treatment, because of limits in care, access and the therapies themselves. Current options are oral immunotherapy and omalizumab, sold as Xolair, which the FDA approved for food allergy. According to MedPage Today, the only FDA approved peanut oral immunotherapy product recently left the market, and clinicians now often use commercial peanut flour instead. Lieberman said a new approach could still find a place. Peptide based immune treatments have a mixed record across medicine, as shown by the recent pancreatic cancer vaccine camupepimut, which missed its main goal, so confirmation in larger groups matters before any claim of benefit.
What happens after the PVX108 readout
Children were challenged again at month 18, after six months without any shots. Aravax said the effects were maintained or had improved compared with month 12, which Vickery described as a hint that the treatment may change the course of the disease. He added that this still needs confirmation. Of the 68 children who completed the main phase, 59 enrolled in a 12 month open label extension, where everyone receives the drug. Aravax expects results from that extension in the second half of 2027. Full trial data are due at a European allergy meeting in Utrecht on 20 November, according to the Aravax results announcement.
The best length of treatment is not known. Vickery noted that allergy shots for other triggers usually run for three to five years, so longer courses may be needed or may work better. Aravax chief executive Pascal Hickey called PVX108 "the first therapy designed to precisely target the root cause of peanut allergy," a company claim that has not been tested in a head to head study. The company says it is planning further trials but has not named a Phase 3 design, size or start date. The PVX108 peanut allergy program now needs a larger randomized study to show whether the 12 month gain holds. More readouts appear on the Peptide Zone trials desk.
Conclusion
The PVX108 peanut allergy trial gives early evidence that a monthly peptide shot can raise the amount of peanut a child tolerates without the reactions seen with whole peanut protein. The effect was modest, the higher dose group held 23 children, and the data are not yet peer reviewed. Long term follow up and a larger confirmatory trial will decide whether this approach earns a place beside oral immunotherapy and omalizumab.